vs
Priority Technology Holdings, Inc.（PRTH）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
Priority Technology Holdings, Inc.的季度营收约是VERACYTE, INC.的1.8倍（$247.1M vs $139.1M），VERACYTE, INC.净利率更高（20.6% vs 3.6%，领先17.0%），VERACYTE, INC.同比增速更快（21.5% vs 8.8%），过去两年VERACYTE, INC.的营收复合增速更高（10.2% vs 9.6%）
Priority Technology Holdings, Inc.是一家聚焦信息技术领域的企业，业务围绕计算机、通信系统等相关信息设备展开，涵盖信息的创建、处理、存储、检索与传输等相关信息技术应用服务，依托计算机科学与工程技术支撑业务开展。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
PRTH vs VCYT — 直观对比
营收规模更大
PRTH
是对方的1.8倍
$139.1M
营收增速更快
VCYT
高出12.7%
8.8%
净利率更高
VCYT
高出17.0%
3.6%
两年增速更快
VCYT
近两年复合增速
9.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $139.1M |
| 净利润 | $8.9M | $28.7M |
| 毛利率 | — | 72.7% |
| 营业利润率 | 13.6% | 16.3% |
| 净利率 | 3.6% | 20.6% |
| 营收同比 | 8.8% | 21.5% |
| 净利润同比 | 23.9% | — |
| 每股收益（稀释后） | $0.10 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRTHVCYT
| Q1 26 | — | $139.1M | ||
| Q4 25 | $247.1M | $140.6M | ||
| Q3 25 | $241.4M | $131.9M | ||
| Q2 25 | $239.8M | $130.2M | ||
| Q1 25 | $224.6M | $114.5M | ||
| Q4 24 | $227.1M | $118.6M | ||
| Q3 24 | $227.0M | $115.9M | ||
| Q2 24 | $219.9M | $114.4M |
净利润PRTHVCYT
| Q1 26 | — | $28.7M | ||
| Q4 25 | $8.9M | $41.1M | ||
| Q3 25 | $27.6M | $19.1M | ||
| Q2 25 | $10.9M | $-980.0K | ||
| Q1 25 | $8.3M | $7.0M | ||
| Q4 24 | $7.2M | $5.1M | ||
| Q3 24 | $10.6M | $15.2M | ||
| Q2 24 | $994.0K | $5.7M |
毛利率PRTHVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% |
营业利润率PRTHVCYT
| Q1 26 | — | 16.3% | ||
| Q4 25 | 13.6% | 26.4% | ||
| Q3 25 | 15.6% | 17.4% | ||
| Q2 25 | 15.6% | -4.0% | ||
| Q1 25 | 14.5% | 2.5% | ||
| Q4 24 | 15.0% | 3.5% | ||
| Q3 24 | 16.8% | 10.4% | ||
| Q2 24 | 15.1% | 4.0% |
净利率PRTHVCYT
| Q1 26 | — | 20.6% | ||
| Q4 25 | 3.6% | 29.3% | ||
| Q3 25 | 11.4% | 14.5% | ||
| Q2 25 | 4.5% | -0.8% | ||
| Q1 25 | 3.7% | 6.2% | ||
| Q4 24 | 3.2% | 4.3% | ||
| Q3 24 | 4.7% | 13.1% | ||
| Q2 24 | 0.5% | 5.0% |
每股收益（稀释后）PRTHVCYT
| Q1 26 | — | $0.35 | ||
| Q4 25 | $0.10 | $0.50 | ||
| Q3 25 | $0.34 | $0.24 | ||
| Q2 25 | $0.14 | $-0.01 | ||
| Q1 25 | $0.10 | $0.09 | ||
| Q4 24 | $-0.05 | $0.07 | ||
| Q3 24 | $0.07 | $0.19 | ||
| Q2 24 | $-0.23 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.2M | $439.1M |
| 总债务越低越好 | $1.0B | — |
| 股东权益账面价值 | $-100.4M | $1.3B |
| 总资产 | $2.4B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRTHVCYT
| Q1 26 | — | $439.1M | ||
| Q4 25 | $77.2M | $362.6M | ||
| Q3 25 | $57.0M | $315.6M | ||
| Q2 25 | $50.6M | $219.5M | ||
| Q1 25 | $47.6M | $186.1M | ||
| Q4 24 | $58.6M | $239.1M | ||
| Q3 24 | $41.1M | $274.1M | ||
| Q2 24 | $34.6M | $235.9M |
总债务PRTHVCYT
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $997.5M | — | ||
| Q2 25 | $917.0M | — | ||
| Q1 25 | $918.9M | — | ||
| Q4 24 | $920.9M | — | ||
| Q3 24 | $808.1M | — | ||
| Q2 24 | $809.0M | — |
股东权益PRTHVCYT
| Q1 26 | — | $1.3B | ||
| Q4 25 | $-100.4M | $1.3B | ||
| Q3 25 | $-110.3M | $1.3B | ||
| Q2 25 | $-146.1M | $1.2B | ||
| Q1 25 | $-158.3M | $1.2B | ||
| Q4 24 | $-166.8M | $1.2B | ||
| Q3 24 | $-165.8M | $1.2B | ||
| Q2 24 | $-172.1M | $1.1B |
总资产PRTHVCYT
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.4B | $1.4B | ||
| Q3 25 | $2.2B | $1.4B | ||
| Q2 25 | $2.0B | $1.3B | ||
| Q1 25 | $1.9B | $1.3B | ||
| Q4 24 | $1.8B | $1.3B | ||
| Q3 24 | $1.8B | $1.3B | ||
| Q2 24 | $1.7B | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $36.8M | $35.2M |
| 自由现金流经营现金流 - 资本支出 | $30.9M | — |
| 自由现金流率自由现金流/营收 | 12.5% | — |
| 资本支出强度资本支出/营收 | 2.4% | — |
| 现金转化率经营现金流/净利润 | 4.12× | 1.23× |
| 过去12个月自由现金流最近4个季度 | $75.1M | — |
8季度趋势，按日历期对齐
经营现金流PRTHVCYT
| Q1 26 | — | $35.2M | ||
| Q4 25 | $36.8M | $52.6M | ||
| Q3 25 | $36.1M | $44.8M | ||
| Q2 25 | $17.1M | $33.6M | ||
| Q1 25 | $10.0M | $5.4M | ||
| Q4 24 | $23.8M | $24.5M | ||
| Q3 24 | $19.8M | $30.0M | ||
| Q2 24 | $28.7M | $29.6M |
自由现金流PRTHVCYT
| Q1 26 | — | — | ||
| Q4 25 | $30.9M | $48.8M | ||
| Q3 25 | $30.1M | $42.0M | ||
| Q2 25 | $9.2M | $32.3M | ||
| Q1 25 | $4.9M | $3.5M | ||
| Q4 24 | $19.1M | $20.4M | ||
| Q3 24 | $14.5M | $27.7M | ||
| Q2 24 | $23.6M | $26.8M |
自由现金流率PRTHVCYT
| Q1 26 | — | — | ||
| Q4 25 | 12.5% | 34.7% | ||
| Q3 25 | 12.5% | 31.8% | ||
| Q2 25 | 3.8% | 24.8% | ||
| Q1 25 | 2.2% | 3.1% | ||
| Q4 24 | 8.4% | 17.2% | ||
| Q3 24 | 6.4% | 23.9% | ||
| Q2 24 | 10.7% | 23.4% |
资本支出强度PRTHVCYT
| Q1 26 | — | — | ||
| Q4 25 | 2.4% | 2.7% | ||
| Q3 25 | 2.5% | 2.1% | ||
| Q2 25 | 3.3% | 1.0% | ||
| Q1 25 | 2.3% | 1.6% | ||
| Q4 24 | 2.0% | 3.5% | ||
| Q3 24 | 2.3% | 1.9% | ||
| Q2 24 | 2.3% | 2.4% |
现金转化率PRTHVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | 4.12× | 1.28× | ||
| Q3 25 | 1.31× | 2.34× | ||
| Q2 25 | 1.57× | — | ||
| Q1 25 | 1.20× | 0.76× | ||
| Q4 24 | 3.29× | 4.80× | ||
| Q3 24 | 1.87× | 1.98× | ||
| Q2 24 | 28.87× | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRTH
暂无分部数据
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
